In today’s briefing:
- Celltrion (068270 KS): Humira Biosimilar Launch in US; Filed New Biosimilar Marketing Application
- Guangzhou Wondfo Biotech (300482.CH) – Time to Bottom Fish?
- Hologic Inc.: 3 Key Drivers & Strategic Priorities Driving Growth – Financial Forecasts
![](http://www.smartkarma.com/assets/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif)
Celltrion (068270 KS): Humira Biosimilar Launch in US; Filed New Biosimilar Marketing Application
- Celltrion Inc (068270 KS) has launched Humira biosimilar Yuflyma in the U.S. market, with a list price of $6,576.50 per month, 5% cheaper than Humira.
- Yuflyma is a citrate-free formulation that is highly concentrated. More than 80% of patients treated with Humira in the U.S. rely on a high-concentration and citrate-free formulation.
- Celltrion has submitted marketing application to the FDA for Eylea biosimilar candidate, CT-P42. The company plans to file for approval for the same in Europe and other countries later.
Guangzhou Wondfo Biotech (300482.CH) – Time to Bottom Fish?
- COVID-19 didn’t bring Wondfo explosive performance growth because China’s official COVID-19 detection method is nucleic acid test while Wondfo’s strength is antigen detection,which is used in later stage of COVID-19.
- Revenue growth would slow down in 2023 due to the high base last year.2023 is a good time to bottom fish this stock as Wondfo’s performance growth would recover afterwards.
- After continuous corrections, the current valuation is already at a low level, and has already priced in the negative impact of the decline in COVID-19 business and IVD centralized procurement.
Hologic Inc.: 3 Key Drivers & Strategic Priorities Driving Growth – Financial Forecasts
- Hologic managed to exceed the revenue expectations as well as the earnings expectations of Wall Street.
- The company’s financial results surpassed expectations, driven by robust organic revenue growth in key divisions like Diagnostics, Surgical, and Breast Health excluding COVID-19, driven by new products, market expansion and customer loyalty.
- Hologic’s COVID-19 assay revenue was $233 million, down 47% sequentially, reflecting lower testing demand and increased competition.